BridgeBio Pharma, Inc.
BBIO
$32.89
$0.702.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -57.63% | 8.45% | 53.48% | 74.87% | -22.21% |
| Total Depreciation and Amortization | -13.75% | -6.16% | -3.85% | -2.27% | -4.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 180.35% | -162.18% | -440.33% | 51.07% | -36.12% |
| Change in Net Operating Assets | -41.10% | -263.39% | 1,716.18% | -608.13% | 87.09% |
| Cash from Operations | -56.49% | -24.33% | 165.90% | -52.12% | -33.86% |
| Capital Expenditure | 89.20% | 68.21% | 87.38% | -5,691.67% | 45.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -964.50% | 0.77% | -29.82% | 83.00% | -98.03% |
| Cash from Investing | -4,804.55% | 1.44% | -26.22% | 85.01% | -100.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 755.26% | -99.31% | -- | 119.39% | -93.22% |
| Repurchase of Common Stock | 45.05% | 44.71% | -66.00% | -473.44% | -422.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,095.70% | 100.00% | -216.27% | -313.37% | -217.58% |
| Cash from Financing | 10,578.24% | -99.77% | -365.39% | 86.06% | -170.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 312.79% | -171.00% | 165.19% | 354.12% | -87.82% |
